Fulcrum Therapeutics, Inc. - Common Stock, $0.001 par value per share (FULC)

Historical Holders from Q3 2019 to Q3 2025

Symbol
FULC on Nasdaq
Type / Class
Equity / Common Stock, $0.001 par value per share
Shares outstanding
54,053,214
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
53,777,314
Holdings value
$494,788,979
% of all portfolios
0.001%
Number of holders
126
Number of buys
62
Number of sells
-61
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Fulcrum Therapeutics, Inc. - Common Stock, $0.001 par value per share (FULC)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 11.2% $55,938,590 6,053,960 RA Capital Management, L.P. 08 Dec 2025
SUVRETTA CAPITAL MANAGEMENT, LLC 9.4% +51.7% $18,495,988 +$6,069,154 5,067,394 +48.8% SUVRETTA CAPITAL MANAGEMENT, LLC 31 Mar 2025
Nantahala Capital Management, LLC 7.66% $17,439,379 4,777,912 Nantahala Capital Management, LLC 30 Sep 2024
BlackRock, Inc. 6% -18.8% $30,090,560 -$7,016,336 3,270,322 -18.9% BlackRock, Inc. 30 Sep 2025
Adage Capital Management, L.P. 4.5% -44.4% $22,374,400 -$19,844,400 2,432,000 -47% Adage Capital Management, L.P. 30 Sep 2025

Institutional Holders of Fulcrum Therapeutics, Inc. - Common Stock, $0.001 par value per share (FULC)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 53,777,314 $494,788,979 -$1,394,513 $9.2 126
2025 Q2 54,400,644 $374,498,177 +$23,533,452 $6.88 122
2025 Q1 51,307,184 $147,764,693 -$3,070,431 $2.88 115
2024 Q4 51,666,381 $242,831,448 -$8,308,464 $4.7 117
2024 Q3 54,857,560 $195,845,950 -$86,380,213 $3.57 127
2024 Q2 64,752,304 $401,470,762 +$19,716,085 $6.2 120
2024 Q1 60,342,845 $569,639,654 -$2,974,963 $9.44 122
2023 Q4 61,083,723 $412,326,970 +$14,153,071 $6.75 100
2023 Q3 56,394,454 $250,394,156 +$9,019,379 $4.44 79
2023 Q2 55,518,138 $183,197,485 -$14,257,183 $3.3 85
2023 Q1 60,413,854 $172,155,022 +$51,602 $2.85 115
2022 Q4 50,644,890 $368,693,025 -$13,010,376 $7.28 109
2022 Q3 52,209,184 $422,360,458 +$98,764,326 $8.09 104
2022 Q2 40,127,745 $196,621,873 -$32,729,118 $4.9 97
2022 Q1 39,071,704 $923,864,555 +$64,674,079 $23.65 104
2021 Q4 37,197,291 $657,236,909 -$42,835,792 $17.69 107
2021 Q3 36,552,286 $1,031,536,477 +$305,128,643 $28.21 100
2021 Q2 26,798,436 $280,833,000 -$3,275,840 $10.48 66
2021 Q1 26,913,060 $317,031,000 +$45,552,581 $11.78 68
2020 Q4 22,170,825 $259,615,000 +$20,231,071 $11.71 65
2020 Q3 20,593,739 $163,306,000 -$36,882,837 $7.93 53
2020 Q2 20,455,938 $373,550,782 +$66,390,720 $18.29 60
2020 Q1 16,827,383 $200,921,119 +$11,941,010 $11.94 46
2019 Q4 15,784,835 $262,061,000 +$1,373,802 $16.64 38
2019 Q3 15,905,791 $105,135,052 +$105,135,052 $6.64 39